A first type of blood test was recently withdrawn from American Food and Drug Administration to detect amyloid plates in the brain associated with Alzheimer’s disease. An Indiana University School of Medicine researcher, who helped lead to the discovery and development of one of the biomarckers, which identifies the test that it would provide more access and more accurate diagnosis for patients.

The test received FDA withdrawal, which allows medical devices to be legally marketed in the US on 16 May. 55 and older people who display symptoms and symptoms of Alzheimer’s disease can now obtain tests, which is more than 90% accurate in diagnosing the disease through a blood draw ordered by their physician.

Jeff Days, Senior Research Professor at Neurology at Jeff, PhD, IU School of Medicine, revealed almost a decade ago that phosphorilated tau – a protein in the brain that is associated with Alzheimer’s disease and is filtered through bloodstream – has a capacity. Biomarker For Alzheimer’s disease. In collaboration with Maio Clinic, Lund University in Sweden, University of San Francisco University and Columbia University, Days worked to demonstrate the performance of blood tests in a wide population of patients.

Teams published landmark papers from 2018 to 2020, identifying a useful blood-based tests, establishing. Their results showed that the test was 96% accurate in determining whether a patient had a pathological evidence of the disease – FDA -Clear Cerebrospinal Fluid Test or PET scan with a scan.

Blood test measures the ratio of two proteins that are the hallmark characteristics of the Alzheimer’s disease: phosphorilated tau (PTAU217) and an amyloid protein (β-amyloid 1-42).

This provides less aggressive, more accessible and scalable method to identify Alzheimer’s pathology in the disease process. It opens the door for more efficient diagnosis, earlier intervention and widespread participation in clinical trials, which is necessary to pursue treatment. ,

Senior Research Professor of Jeff Days, PhD, Neurology, IU School of Medicine

According to the Alzheimer’s Association, more than 7 million people in the US are living with Alzheimer’s disease, and the number is estimated to increase by about 13 million in 2050.

For nearly 15 years, doctors detected amymeloid plates to diagnose Alzheimer’s disease using the positron emission tomography (PET) brain scan, and, in 2022, the FDA collected samples of the cerebrospinal liquids through a punch of lumbar to detect plates. Those methods, however, are more aggressive, more expensive and less accessible for all types of patients.

“Now we can get tens of tens of patients more specific and accurate diagnosis and especially the risk associated with Alzheimer’s disease or non-alzheimer’s disease or our understanding of protective factors can improve our understanding,” Dedes said.

Since the blood test turns into a health care industry and doctors become more comfortable with its performance, Dads said it can provide first diagnosis for patients.

Dads, who joined the IU School of Medicine Faculty in 2021 after more than 20 years as a scientist at Elli Lily & Co., said that it is personal for him to develop an inexpensive and accessible blood test to help in the diagnosis of Alzheimer’s disease. He began his discovery of a blood-based biomarker only a few years after his mother undergoing a career for her mother, who undergone the complexities of dementia in 2019.

“While the test is a major milestone, we should continue to refine it, expand its use and ensure that it reaches those who need the most,” Days said. “Above all, I am grateful to patients and families who have participated in our research – they are the true heroes of this story. I hope more people will get excited about participating in research and even donate brain and blood so that we can search for next.”

The Biomarker Research is an emerging aspect of the IU School of Medicine’s comprehensive Alzheimer’s disease research program, including basic and translational research, discovery of drug, new therapeutic and clinical research testing.

The expertise of Days at Baymarker has supported several Alzheimer’s Research Programs at the Medical School, such as Indiana Alzheimer’s Disease Research Center, longitudinal initial beginnings Alzheimer’s disease studies, target efficiency to accelerate medical development for the Alzheimer’s Center for Alzheimer’s Disease Center and national centralized repository for Alzheimer.

Bruce Lamb, PhD, an IU iconic professor and Executive Director of Stark Neuroscience Research Institute, said that Fluid Biomarckers examine the basic, translation and clinical research checking Alzheimer’s disease and related demented at the IU School of Medicine.

“This program has allowed us to identify and validate the biomarkers of the disease in the animal model, identify unique biomarkers associated with medical goals, patients in the population and clinical trials characterize the novel fluid biomarker and apply to the biomarckers in the community,” said the lamb.